GeoVax to Present Pipeline Updates at H.C. Wainwright Investment Conference

GeoVax Labs, Inc. Chairman and CEO David Dodd will present a company overview and host investor meetings during the H.C. Wainwright 27th Annual Global Investment Conference in New York City from September 8-10, 2025. The presentation will focus on recent progress and upcoming milestones across the company's pipeline of multi-antigen vaccines and immunotherapies for infectious diseases and cancer.

The company will discuss GEO-MVA, a next-generation MVA-based Mpox/smallpox vaccine positioned to support global preparedness and stockpile strategies. This program recently received favorable Scientific Advice from the European Medicines Agency, potentially accelerating its development pathway. The regulatory guidance suggests the company may progress directly to Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials, which could significantly shorten the timeline to potential approval.

GeoVax will also provide updates on GEO-CM04S1, its multi-antigen COVID-19 vaccine currently being evaluated in three Phase 2 clinical trials. These trials are assessing the vaccine across various patient populations, including immunocompromised individuals such as those suffering from hematologic cancers and patients with chronic lymphocytic leukemia. The vaccine is being studied as both a primary vaccine for populations where current authorized COVID-19 vaccines are insufficient and as a booster for healthy patients who previously received mRNA vaccines.

The oncology program Gedeptin®, a gene-directed enzyme prodrug therapy for solid tumors, will also be featured. The company recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers and is preparing for an upcoming Phase 2 trial. This therapy represents a novel approach to treating solid tumors that could address unmet medical needs in cancer treatment.

GeoVax will highlight how its MVA platform and U.S.-based continuous cell line manufacturing capabilities position the company to address critical gaps in vaccine supply diversification, pandemic readiness, and biosecurity. The webcast of the presentation will be available beginning at 7:00 am ET on September 8, 2025, at https://journey.ct.events/view/40d09ded-caa5-44ff-baf7-10795e9d5386. The company's technology portfolio and development progress can be followed through their corporate website at https://www.geovax.com.